Yoon-Koo Kang
University of Ulsan
H-index: 99
Asia-South Korea
Top articles of Yoon-Koo Kang
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Clinical outcomes of Epstein–Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine … | Gastric Cancer | Eo Jin Kim Heejung Chae Young-Soo Park Min-Hee Ryu Hyung-Don Kim | 2024/1 |
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial | Gastric Cancer | Zev A Wainberg Yoon-Koo Kang Keun-Wook Lee Shukui Qin Kensei Yamaguchi | 2024/2/3 |
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040 | Annals of Oncology | AB El-Khoueiry Jörg Trojan Tim Meyer Thomas Yau Ignacio Melero | 2024/4/1 |
DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and … | Gastric Cancer | Jaewon Hyung Hyungwoo Cho Hyung-Don Kim Young Soo Park Meesun Moon | 2024/1 |
Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses … | John Raymond Zalcberg Robin Lewis Jones Jean-Yves Blay Suzanne George Hans Gelderblom | 2024/1/20 | |
Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer | European Journal of Surgical Oncology | Su Mi Kim Ji Yeong An Sun-ju Byeon Jeeyun Lee Kyoung-Mee Kim | 2020/1/1 |
GASTric Cancer HER2 Re-Assessment Study 2 (GASTHER2): HER2 Re-assessment for Initially HER2-Negative Advanced Gastric Cancer Patients after Progression on First-Line Treatment | Cancer Research and Treatment: Official Journal of Korean Cancer Association | Jaewon Hyung Hyung-Don Kim Min-Hee Ryu Young Soo Park Meesun Moon | 2024/1 |
62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT … | ESMO Open | JY Blay RL Jones H Gelderblom S George P Schöffski | 2024/3/1 |
Results from a phase 2 study of triplet blockade of the IL-27, PD-(L) 1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and … | Daneng Li Kun-Ming Rau Ming-Lung Yu Hong Jae Chon Hsueh-Chou Lai | 2024/1/20 | |
Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors. | Cancer Research and Treatment | Yoon-Koo Kang Min-Hee Ryu Yong Sang Hong Chang-Min Choi Tae Won Kim | 2024/1/18 |
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an … | Gastric Cancer | Yoon-Koo Kang Min-Hee Ryu Maria Di Bartolomeo Ian Chau Harry Yoon | 2024/3 |
Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs) | Sejin Kim Hyung-Don Kim Eo Jin Kim Min-Hee Ryu Yoon-Koo Kang | 2024/4/8 | |
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial | Nature medicine | Michael C Heinrich Robin L Jones Suzanne George Hans Gelderblom Patrick Schöffski | 2024/1/5 |
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma | Annals of Oncology | B Sangro SL Chan RK Kelley G Lau M Kudo | 2024/2/19 |
Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ … | Jeeyun Lee Ardaman Shergill Haeseong Park Keun-Wook Lee Hendrik-Tobias Arkenau | 2023/6/1 | |
Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions | Gastric Cancer | Yoon-Koo Kang Hyung-Don Kim Hyun Jin Kim Young Soo Park Mo-Youl Beck | 2023/7 |
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study | European Journal of Cancer | Hans Gelderblom Robin L Jones Jean-Yves Blay Suzanne George Margaret von Mehren | 2023/10/1 |
1526P Phase Ib results of bemarituzumab (BEMA)+ mfolfox6+ nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1 | Annals of Oncology | ZA Wainberg K Yamaguchi JA Ajani J Chao M Moehler | 2023/10/1 |
147P Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) | Annals of Oncology | SL Chan B Sangro RK Kelley G Lau M Kudo | 2023/11/1 |
Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer. | Keun-Wook Lee Hark Kyun Kim Min-Hee Ryu Dae Young Zang Ji-Won Kim | 2023/2/1 |
